Results 31 to 40 of about 92,889 (88)

Rapport Général de la Question 103 "Petits barrages et digues"

, 2018
[Departement_IRSTEA]Eaux [TR1_IRSTEA]RIVAGE [ADD1_IRSTEA]Hydrosystèmes et risques naturelsInternational audienceThis document is the General Report of Question 103 of the ICOLD Congresses, "Small Dams and Levees". It presents a synthesis of the 47 papers
Tourment, R.
core  

Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach. [PDF]

Mol Med, 2021
Miranda J, Bringas R, Fernandez-de-Cossio J, Perera-Negrin Y.   +3 more
europepmc   +1 more source

Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. [PDF]

Immunotherapy, 2022
Londres HD, Armada JJ, Martínez AH, Abdo Cuza AA, Sánchez YH, Rodríguez AG, Figueroa SS, Llanez Gregorich EM, Torres Lahera ML, Peire FG, González TM, González YZ, Añé Kouri AL, Palomo AG, Concepción MT, Pérez LM, Luaces-Alvarez PL, Iglesias DE, Hernández DS, Suzarte MR, Ramos TC.   +20 more
europepmc   +1 more source

CIGB-300 internalizes and impairs viability of NSCLC cells lacking actionable targets by inhibiting casein kinase-2 signaling

Overall response rates in advanced Non-Small Cell Lung Cancer (NSCLC) remains low. Thus, novel molecular targets, tailored drugs and/or drug combinations are needed.
Yaqin Lan, Guirong Zeng, Ying Yi, Lingfeng Dai, Silvio E. Perea, Dejian Jiang, Dania M. Vázquez-Blomquist, Ke Yang, Yasser Perera, Changyuan Tan   +9 more
core   +1 more source

Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study). [PDF]

EClinicalMedicine, 2023
Cinza-Estévez Z, Resik-Aguirre S, Figueroa-Baile NL, Oquendo-Martínez R, Campa-Legrá I, Tejeda-Fuentes A, Rivero-Caballero M, González-García G, Chávez-Chong CO, Alonso-Valdés M, Hernández-Bernal F, Lemos-Pérez G, Campal-Espinosa A, Freyre-Corrales G, Benítez-Gordillo D, Gato-Orozco E, Pérez Bartutis GS, Mesa-Pedroso I, Bueno-Alemani N, Infante-Aguilar E, Rodríguez Reinoso JL, Melo-Suarez G, Limonta-Fernández M, Ayala-Ávila M, Muzio-González VL, ISMAELILLO Clinical Trial Group.   +25 more
europepmc   +1 more source

The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases. [PDF]

J Neuroimmunol, 2021
Cama VF, Marín-Prida J, Acosta-Rivero N, Acosta EF, Díaz LO, Casadesús AV, Fernández-Marrero B, Gilva-Rodríguez N, Cremata-García D, Cervantes-Llanos M, Piniella-Matamoros B, Sánchez D, Del Rosario-Cruz L, Borrajero I, Díaz A, González Y, Pentón-Arias E, Montero-González T, Guillen-Nieto G, Pentón-Rol G.   +19 more
europepmc   +1 more source

Synthesis, LC-MS/MS analysis, and biological evaluation of two vaccine candidates against ticks based on the antigenic P0 peptide from R. sanguineus linked to the p64K carrier protein from Neisseria meningitidis. [PDF]

Anal Bioanal Chem, 2021
González LJ, Encinosa Guzmán PE, Machado W, Pousa S, Leyva A, Arguelles ALC, Cabrera G, Espinosa LA, Parra R, Hernández R, Soto YB, Ledesma FL, Joglar M, Guirola O, Kurt LU, Carvalho PC, Cabrales A, Garay H, Besada V, Durán R, Takao T, Estrada MP, Rodríguez-Mallon A.   +22 more
europepmc   +1 more source

The synthetic peptide CIGB-300 competes with Rev and US11 by binding NPM1^OD with high-affinity.

, 2015
(A) CIGB-300 consists of the cyclic P15 (blue) and the Tat (purple) peptides, and labeled with fluorescein (green; FITC). (B) Fluorescence polarization experiments conducted by titrating increasing amounts of NMP1 variants, Rev, US11, and GST to 0.1 μM ...
Jens M. Moll (540876), Hartmut Hengel (208204), Anika Hain (832279), Sebastian Howe (832283), Lutz Schmitt (219319), Lech-Gustav Milroy (832278), Sander H. J. Smits (219308), Luitgard Nagel-Steger (235551), Carsten Münk (48572), Luc Brunsveld (540877), Michael Lenders (832282), Mohammad R. Ahmadian (540878), Ehsan Amin (832281), Radovan Dvorsky (832280), Kazem Nouri (540874)   +14 more
core   +1 more source

Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise. [PDF]

Mol Cell Biochem, 2023
Trembley JH, Kren BT, Afzal M, Scaria GA, Klein MA, Ahmed K.   +5 more
europepmc   +1 more source

An overview on the treatments and prevention against COVID-19. [PDF]

Virol J, 2023
Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, Mellatyar H.   +6 more
europepmc   +1 more source